eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy - a phase III intergroup study

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
    PEG-interferon alfa-2b
  5. Intervention
  6. Intervention
  7. Intervention
    Doxorubicin hydrochloride
  8. Additional Topic(s)
    MAP therapy
  9. Resource Description
    The standard anti-cancer drugs used to treat patients with osteosarcoma are doxorubicin, cisplatin, and methotrexate (together called MAP therapy). In previous research studies using MAP, it was found that if the tumor cells are almost all destroyed (about 90% or more, called a good response) by MAP, there is a good chance that the tumor can be cured by continuing to use these standard drugs. If the tumor cells are not as easily killed by MAP (less than 90% of the cells killed, called a poor response), the chance of cure is not as good, meaning the tumor is more likely to return later. For children and adolescents who do not have a good tumor response to MAP, this study aims to find out if adding two other common anti-cancer drugs (ifosfamide and etoposide) will help cure more patients. For children and adolescents who have a good tumor response to MAP therapy, study doctors would like to know if adding a “biologic” drug, interferon, after MAP, will help make sure the tumor cells do not return later. The aims of this study are: To see if the addition of ifosfamide and etoposide to MAP chemotherapy will help cure patients who have a poor tumor response to MAP alone. To see if the addition of interferon after MAP chemotherapy can help improve cure rates in children and adolescents who have a good tumor response to standard chemotherapy.
  10. Additional Name
    Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
  11. Topic
  12. Study Population
    Males and females between ages 5 and 40 with high grade osteosarcoma, including second malignancies, which meet other tumor-related and laboratory test requirements
  13. Funded by
    Children's Oncology Group
  14. Phase
    Phase 3 clinical trial
  15. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016